SPI Infoamtion

Table of Contents

1. Executive Summary
1.1 AMD & Diabetic Retinopathy Market Review
1.2 Aim, Scope and Format of the Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. Macular Degeneration and Diabetic Retinopathy
2.1 Vision
2.1.1 The Human Eye
2.1.2 The Retina and the Vision Process
2.2 Age-Related Macular Degeneration (AMD)
2.2.1 Early Stages of AMD
2.2.2 Advanced Dry AMD (Geographic Atrophy)
2.2.3 Wet AMD
2.2.4 Causes and Risk Factors for AMD
2.3 Diabetic Retinopathy (DR)
2.3.1 Causes and Types of Diabetic Retinopathy
2.3.2 Non-Proliferative Diabetic Retinopathy
2.3.3 Diabetic Macular Oedema
2.3.4 Proliferative Diabetic Retinopathy (PDR)
2.3.5 Risk Factors for Diabetic Retinopathy
2.4 Diagnosis
2.5 Epidemiology
2.6 Other Retinal Disorders

3. The World Market for AMD and Diabetic Retinopathy Drugs
3.1 World AMD and DR Market Forecasts 2010-2025
3.2 AMD Market Forecast 2010-2025
3.3 Diabetic Retinopathy Market
3.4 Market Shares
3.5 Leading Companies in the Sector

4. Treatments for AMD and Diabetic Retinopathy
4.1 Treatment of Wet AMD
4.1.1 Visudyne
4.1.1.1 Visudyne: Forecast and Analysis 2010-2025
4.1.2 Macugen
4.1.2.1 Macugen: Forecast and Analysis 2010-2025
4.1.3 Retaane
4.1.4 Lucentis
4.1.4.1 Lucentis: Forecast and Analysis 2010-2025
4.1.5 Avastin
4.1.5.1 Avastin: Forecast and Analysis 2010-2025
4.2 Treatment of Dry AMD
4.2.1 Nutritional Supplements
4.2.2 Intraocular Lenses
4.3 Treatments for Diabetic Retinopathy
4.3.1 Laser and Other Surgical Treatments
4.3.2 Triamcinolone Acetonide
4.3.3 Lisinopril
4.3.4 VEGF Inhibitors
4.3.5 Dobesilate

5. AMD and Diabetic Retinopathy: Leading National Markets
5.1 US: Sales Prospects 2010-2025
5.2 France: Sales Prospects 2010-2025
5.3 Japan: Sales Prospects 2010-2025
5.4 Germany: Sales Prospects 2010-2025
5.5 UK: Sales Prospects 2010-2025
5.6 Spain: Sales Prospects 2010-2025
5.7 Australia: Sales Prospects 2010-2025
5.8 Canada: Sales Prospects 2010-2025
5.9 China: Sales Prospects 2010-2025
5.10 India: Sales Prospects 2010-2025
5.11 Comparing the National Markets

6. Issues Affecting the AMD and DR Pharmaceutical Markets
6.1 SWOT Analysis of the AMD and DR Pharmaceutical Markets
6.2 Intense Research and Development Activity
6.2.1 New Drug Formulations
6.2.2 Sustained-Release Ocular Implants
6.2.3 Novel Biologic Drugs
6.2.4 New Ophthalmic Therapeutic Applications for Drugs
6.3 The Avastin-Lucentis Debate
6.3.1 Avastin and Lucentis
6.3.2 Off-Label Retinal Applications of Avastin
6.3.3 History of Avastin Use for Wet AMD
6.3.4 The CATT Study
6.3.5 The Future for Off-Label Avastin Use
6.4 Aging of the World Population Increases Demand for Treatments
6.5 Prevalence of Retinal Disorders
6.5.1 Prevalence of AMD in 2009
6.5.2 AMD Prevalence 2009-2025
6.5.3 Prevalence of Diabetes, Proliferative Diabetic Retinopathy and Diabetic Macular Oedema, 2009
6.5.4 Prevalence of Diabetic Retinopathy 2009-2025
6.6 Reimbursement for AMD and Diabetic Retinopathy Pharmaceuticals
6.6.1 Pressure on Healthcare in Current Difficult Economic Environment
6.6.2 Prospects for Reimbursement for AMD and DR Drugs
6.7 Diagnosis and Screening for Retinal Disorders
6.8 Laser and Surgical Treatments for Diabetic Retinopathy Will Compete with New Drugs
6.8.1 Current Laser Treatments
6.8.2 Will Drugs Replace Laser Therapy?

7. The AMD and Diabetic Retinopathy R&D Pipelines
7.1 VEGF Trap-Eye/Aflibercept (Regeneron/Bayer)
7.2 Ozurdex/SK-0503 (Allergan/Sanwa Kagaku Kenkyusho)
7.3 Bevasiranib (Opko)
7.4 Avastin and Lucentis Comparison Trials (CATT)
7.5 PF-4523655 (Quark/Pfizer)
7.6 Votrient (pazopanib) (GSK)
7.7 Zybrestat (Oxigene/Symphony ViDA)
7.8 Sirolimus (MacuSight/Santen)
7.9 Iluvien (Alimera/pSivida)
7.10 NT-501 (Neurotech)
7.11 OT-551 (Othera)
7.12 Lucentis (Novartis)
7.13 Macugen (Pfizer)
7.14 Vitreosolve (Vitreoretinal Technologies)
7.15 Microplasmin (ThromboGenics)
7.16 Arxxant (ruboxistaurin, Eli Lilly/Alcon/Takeda)
7.17 Stem Cells

8. Opinion from Industry Experts
8.1 Edward Danse, President and CEO, Neurotech
8.1.1 Retinal Disorders with Greatest Unmet Patient Need
8.1.2 Neurotech's AMD Pipeline
8.1.3 Progress of NT-501 Clinical Trials in Geographic Atrophy Patients
8.1.4 Screening Programmes for AMD
8.1.5 Potential Lifetime of NT-501 in the Eye
8.1.6 Other Potential Treatments for Geographic Atrophy
8.1.7 Potential Use of NT-501 in Diabetic Retinopathy
8.2 Ken Green, Ph.D., Chief Scientific Officer, and Dave Holland, Founder/VP Marketing, Alimera Sciences
8.2.1 Main Unmet Clinical Needs Among Diabetic Retinopathy Patients
8.2.2 Development of Iluvien for Diabetic Macular Oedema
8.2.3 Reimbursement Prospects for Corticosteroid Inserts
8.2.4 Future for Laser Therapy in Diabetic Retinopathy
8.2.5 Possible Future Treatment for Dry AMD and Geographic Atrophy
8.2.6 Clinical Trials of Iluvien for Wet AMD and RVO
8.3 Dr Al Reaves, Ph.D., Senior Vice President of Clinical Development, Othera Pharmaceuticals
8.3.1 Othera's Geographic Atrophy Drug: OT-551
8.3.2 New Drugs for Retinal Disorders Currently with No Treatments

9. Conclusions
9.1 AMD and Diabetic Retinopathy
9.2 Increasing Prevalence of AMD and Diabetic Retinopathy
9.3 Current Treatments for AMD and Diabetic Retinopathy
9.4 The AMD and DR Pharmaceutical Market in 2009
9.5 AMD and Diabetic Retinopathy Pharmaceutical Market Forecast, 2010-2025
9.6 Lucentis Market Forecast, 2010-2025
9.7 The AMD R&D Pipeline
9.8 The Diabetic Retinopathy R&D Pipeline
9.9 Concluding Remarks

List of Tables
Table 2.1 Causes of Blindness Worldwide, 2007
Table 2.2 Wet AMD Types
Table 2.3 AMD and DR Diagnosis Methods
Table 2.4 Incidence and Prevalence of Advanced AMD & DR, 2009
Table 2.5 Cases of Advanced AMD by Age Group, 2009
Table 2.6 Cases of AMD by Age Group, 2009
Table 2.7 Cases of DR by Age Group, 2009
Table 2.8 Other Retinal Disorders
Table 3.1 AMD & DR Pharmaceutical Markets, 2009
Table 3.2 AMD and DR Markets: Revenue Forecasts, 2010-2025
Table 3.3 AMD Pharmaceutical Market: Revenue Forecast, 2010-2025
Table 3.4 DR Pharmaceutical Market: Revenue Forecast, 2010-2025
Table 3.5 AMD and DR: Market Shares, 2010-2025
Table 3.6 AMD & DR Pharmaceutical Markets: Leading Companies, 2009
Table 4.1 AMD and DR Pharmaceutical Markets: Revenue Forecasts, 2010-2025
Table 4.2 Visudyne Sales Breakdown, 2009
Table 4.3 Visudyne: Revenue Forecast, 2010-2025
Table 4.4 Macugen: Revenue Forecast, 2010-2025
Table 4.5 Lucentis: Regulatory Approval and Launch Dates
Table 4.6 Lucentis: Revenue Forecast, 2010-2025
Table 4.7 Avastin: Revenue Forecast, 2010-2025
Table 5.1 AMD & DR Market: Sales in Leading National Markets, 2009
Table 5.2 The US AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.3 French AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.4 Proportion of Leading Markets’ Populations over 65, 2010 and 2030
Table 5.5 Japanese AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.6 German AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.7 UK AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.8 Spanish AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.9 Australian AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.10 Canadian AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.11 Chinese AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.12 Indian AMD & DR Market: Revenue Forecast, 2010-2025
Table 5.13 Comparison of Leading National Markets: Revenue Forecasts, 2010-2025
Table 6.1 SWOT Analysis of Age-Related Macular Degeneration & Diabetic Retinopathy Pharmaceutical Market, 2010
Table 6.2 World Population Aging, 2009-2025
Table 6.3 Number of Over-60s in Selected Countries, 2009 and 2025
Table 6.4 AMD Incidence, 2009-2025
Table 6.5 DR Incidence, 2009-2025
Table 7.1 Key Late-Stage AMD Pipeline Drugs, 2010
Table 7.2 Selected Early-Stage AMD Pipeline Drugs, 2010
Table 7.3 Lucentis Clinical Trials in Progress, 2010
Table 7.4 Key Late-Stage Diabetic Retinopathy Pipeline Drugs, 2010
Table 7.5 Selected Early-Stage DR Pipeline Drugs, 2010
Table 9.1 AMD & DR: Incidence Rates, 2009 and 2025

List of Figures
Figure 2.1 Leading Causes of Blindness Worldwide, 2007
Figure 2.2 How AMD Progresses
Figure 2.3 Incidence and Prevalence of Advanced AMD & DR, 2009
Figure 2.4 Proportion of Advanced AMD Cases by Age Group, 2009
Figure 2.5 Proportion of AMD Cases by Gender, 2009
Figure 2.6 Cases of DR by Age Group, 2009
Figure 3.1 AMD and DR Pharmaceutical Markets, 2009
Figure 3.2 AMD and DR Markets: Revenue Forecasts, 2010-2025
Figure 3.3 AMD Pharmaceutical Market: Revenue Forecast, 2010-2025
Figure 3.4 DR Pharmaceutical Market: Revenue Forecast, 2010-2025
Figure 3.5 AMD and DR: Market Shares, 2010-2025
Figure 3.6 AMD and DR Pharmaceutical Markets: Leading Companies, 2009
Figure 4.1 Visudyne: Sales Breakdown, 2009
Figure 4.2 Visudyne: Revenue Forecast, 2010-2025
Figure 4.3 Macugen: Revenue Forecast, 2010-2025
Figure 4.4 Lucentis: Revenue Forecast, 2010-2025
Figure 4.5 Avastin: Revenue Forecast, 2010-2025
Figure 5.1 AMD & DR Market Shares of Ten Leading Countries, 2009
Figure 5.2 US AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.3 Proportion of Leading Markets’ Populations Aged over 65, 2010 and 2030
Figure 5.4 French AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.5 Japanese AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.6 German AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.7 UK AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.8 Spanish AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.9 Australian AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.10 Canadian AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.11 Chinese AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.12 Indian AMD & DR Market: Revenue Forecast, 2010-2025
Figure 5.13 Leading Country Markets (Upper Tier): Revenue Forecasts, 2010-2025
Figure 5.14 Leading Country Markets (Lower Tier): Revenue Forecasts, 2010-2025
Figure 6.1 World Population Aging, 2009-2025
Figure 6.2 Number of Over-60s in Selected Countries, 2009 and 2025
Figure 6.3 AMD Incidence, 2009-2025
Figure 6.4 Diabetic Retinopathy Incidence Forecast, 2009 and 2025
Figure 9.1 World AMD & DR Pharmaceutical Market Forecasts, 2010-2025
Figure 9.2 Lucentis: Revenue Forecast, 2010-2025